NEW YORK (GenomeWeb News) – Nanogen said after the close of the market on Thursday that amid a restructuring, which included shutting down its microarray business, the firm’s fourth-quarter revenues increased 13 percent.
 
However, in a note accompanying the results, Nanogen said that it expects its independent accountants to issue an adverse opinion with respect to its internal controls and say that “there is substantial doubt about the company’s ability to continue as a going concern.”
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.